GÃ©rald Simonneau

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10380099/publications.pdf

Version: 2024-02-01

336	85,082	735 120	344 285
papers	citations	h-index	g-index

350	350	350	26159
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	2.2	5,074
2	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	2.2	3,108
3	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D34-D41.	2.8	2,865
4	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801913.	6.7	2,583
5	Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2002, 346, 896-903.	27.0	2,545
6	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	6.7	2,415
7	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157.	27.0	2,237
8	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	2.8	1,919
9	Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030.	5.6	1,736
10	A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis. New England Journal of Medicine, 1998, 338, 409-416.	27.0	1,676
11	Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1425-1436.	27.0	1,627
12	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
13	Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12.	2.8	1,542
14	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet, The, 2001, 358, 1119-1123.	13.7	1,421
15	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788.	2.8	1,290
16	Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 800-804.	5.6	1,288
17	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
18	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	27.0	1,168

#	Article	IF	Citations
19	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 319-329.	27.0	1,144
20	Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. New England Journal of Medicine, 1996, 335, 609-616.	27.0	1,127
21	Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home. New England Journal of Medicine, 1996, 334, 682-687.	27.0	1,108
22	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111.	1.6	1,040
23	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
24	New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. Chest, 2004, 126, 1313-1317.	0.8	923
25	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.	27.0	906
26	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	2.2	903
27	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Circulation, 2011, 124, 1973-1981.	1.6	860
28	Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2006, 113, 2011-2020.	1.6	791
29	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	27.0	790
30	A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism. New England Journal of Medicine, 1997, 337, 663-669.	27.0	767
31	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334.	27.0	676
32	Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: Results from an international prospective registry. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 702-710.	0.8	605
33	Medical Therapy For Pulmonary Arterial Hypertension. Chest, 2004, 126, 35S-62S.	0.8	592
34	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502.	2.8	584
35	Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2008, 149, 521.	3.9	558
36	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548

#	Article	IF	Citations
37	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	2.8	541
38	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	6.7	527
39	Pulmonary Hypertension in Chronic Lung Diseases. Journal of the American College of Cardiology, 2013, 62, D109-D116.	2.8	518
40	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	2.8	506
41	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.	1.6	506
42	Increased plasma serotonin in primary pulmonary hypertension. American Journal of Medicine, 1995, 99, 249-254.	1.5	500
43	Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137.	2.5	483
44	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
45	Medical Therapy for Pulmonary Arterial Hypertension. Chest, 2007, 131, 1917-1928.	0.8	477
46	Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation, 2001, 108, 1141-1150.	8.2	446
47	Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 529-535.	2.8	441
48	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018.	1.6	441
49	A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine, 2011, 365, 44-53.	27.0	432
50	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
51	Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 108-113.	5.6	402
52	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125.	14.6	386
53	Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet, The, 2002, 360, 1914-1920.	13.7	384
54	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368

#	Article	IF	Citations
55	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69.	21.4	351
56	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 41, 1380-1386.	2.8	334
57	Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531.	6.7	321
58	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	6.7	319
59	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189.	0.8	316
60	Dysregulated Reninâ€“Angiotensinâ€“Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789.	5.6	309
61	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
62	The pathophysiology of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160112.	7.1	307
63	Prognostic Factors for Survival in Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1433-1439.	5.6	295
64	Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233.	1.0	295
65	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902.	2.0	291
66	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530.	6.7	291
67	Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534.	6.7	289
68	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
69	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208.	1.6	278
70	Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126.	1.3	277
71	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595.	2.2	272
72	Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. Chest, 2003, 124, 247-254.	0.8	271

#	Article	IF	Citations
73	Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thrombosis and Haemostasis, 2014, 112, 598-605.	3.4	271
74	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
75	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 874-880.	6.7	267
76	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861.	5.6	259
77	Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. Circulation, 2006, 113, 1857-1864.	1.6	257
78	Inhibition of Hypoxic Pulmonary Vasoconstriction by Nifedipine. New England Journal of Medicine, 1981, 304, 1582-1585.	27.0	256
79	CX₃C Chemokine Fractalkine in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1419-1425.	5.6	247
80	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal, 2015, 45, 1293-1302.	6.7	247
81	Chemokine RANTES in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 534-539.	5.6	239
82	Bosentan for the Treatment of Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1212-1217.	5.6	238
83	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. Chest, 2011, 140, 1274-1283.	0.8	237
84	Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. American Journal of Roentgenology, 2004, 183, 65-70.	2.2	234
85	Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Chest, 2004, 126, 420-427.	0.8	232
86	Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97.	2.7	226
87	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
88	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907.	2.2	218
89	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	8.2	208
90	Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S81-S88.	2.8	206

#	Article	IF	Citations
91	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
92	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288.	6.7	201
93	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	10.7	201
94	Systematic Lung Scans Reveal a High Frequency of Silent Pulmonary Embolism in Patients With Proximal Deep Venous Thrombosis. Archives of Internal Medicine, 2000, 160, 159.	3.8	197
95	BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Human Mutation, 2006, 27, 212-213.	2.5	196
96	Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047.	5.6	196
97	Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. Circulation Research, 2004, 94, 1263-1270.	4.5	187
98	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523.	8.2	177
99	C-Kitâ€“Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123.	5.6	176
100	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	6.7	173
101	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
102	High Prevalence of Detectable Deep Venous Thrombosis in Patients With Acute Pulmonary Embolism. Chest, 1999, 116, 903-908.	0.8	163
103	Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1681-1685.	5.6	161
104	Pulmonary Arterial Hypertension: A Rare Complication of Primary SjÃ¶gren Syndrome. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	160
105	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
106	Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin. American Journal of Medicine, 1990, 89, 117-120.	1.5	154
107	PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 451-458.	2.1	153
108	Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. Journal of Rheumatology, 2007, 34, 2417-22.	2.0	152

#	Article	IF	Citations
109	Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. Journal of the American College of Cardiology, 2001, 37, 1085-1092.	2.8	151
110	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75.	2.2	149
111	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	3.8	149
112	Surgical Treatments/Interventions for Pulmonary Arterial Hypertension. Chest, 2004, 126, 63S-71S.	0.8	144
113	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141
114	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.9	135
115	Long-term outcome of double-lung and heartâ€“lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patientsâ˜†. European Journal of Cardio-thoracic Surgery, 2010, 38, 277-284.	1.4	130
116	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 372-380.	10.7	130
117	New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216.	5.6	129
118	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946.	0.9	128
119	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
120	Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 311-322.	2.9	125
121	Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538.	13.7	125
122	Tadalafil for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2012, 60, 768-774.	2.8	124
123	Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. European Journal of Cardio-thoracic Surgery, 2015, 47, e105-e110.	1.4	124
124	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	6.7	124
125	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134.	10.7	123
126	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function inÂPulmonary Hypertension. Journal of the American College of Cardiology, 2015, 65, 668-680.	2.8	119

#	Article	IF	Citations
127	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.8	117
128	RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 459-475.	2.1	116
129	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. Annals of Thoracic Surgery, 2012, 94, 817-824.	1.3	116
130	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	6.7	113
131	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 915-917.	6.7	111
132	Systemic sclerosisâ€“related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464.	6.7	109
133	Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1025-1033.	5.6	106
134	Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157.	0.8	104
135	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.6	103
136	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847.	1.6	103
137	Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1061-1067.	5.6	102
138	Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768.	0.8	102
139	Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2013, 41, 224-232.	6.7	100
140	Chronic thromboembolic pulmonary hypertension: role of medical therapy. European Respiratory Journal, 2013, 41, 985-990.	6.7	99
141	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
142	Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S.	0.8	97
143	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	6.7	97
144	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825.	2.9	96

#	Article	IF	Citations
145	Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2013, 110, 83-91.	3.4	96
146	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 632-643.	0.6	95
147	Pulmonary Artery Pressureâ€“Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 338-340.	5.6	94
148	Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32.	2.9	94
149	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	5.6	94
150	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	21.4	93
151	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	6.7	92
152	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500.	1.9	91
153	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.6	91
154	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2021, 78, 1393-1403.	2.8	90
155	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	6.7	89
156	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	6.7	87
157	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
158	Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 798-802.	5.6	83
159	Key Role of the Endothelial TGF-Î²/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension. PLoS ONE, 2014, 9, e100310.	2.5	83
160	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	6.7	83
161	The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146.	2.9	82
162	Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension. Proceedings of the American Thoracic Society, 2006, 3, 608-614.	3.5	82

#	Article	IF	Citations
163	Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164.	6.7	82
164	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	2.8	82
165	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respiratory Research, 2010, 11, 73.	3.6	81
166	Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respiratory Review, 2013, 22, 244-250.	7.1	81
167	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640.	6.7	80
168	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	6.7	80
169	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731.	6.7	80
170	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5.	1.9	77
171	Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172.	6.7	75
172	The changing landscape of chronic thromboembolic pulmonary hypertension management. European Respiratory Review, 2017, 26, 170105.	7.1	69
173	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	2.2	69
174	Chemokine Macrophage Inflammatory Protein-1Î± mRNA Expression in Lung Biopsy Specimens of Primary Pulmonary Hypertension. Chest, 1998, 114, 50S-51S.	0.8	68
175	Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?. European Respiratory Review, 2013, 22, 217-226.	7.1	68
176	BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681.	6.7	68
177	Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68
178	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
179	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119.	3.6	67
180	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67

#	Article	IF	Citations
181	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
182	Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Research, 2021, 7, 00850-2020.	2.6	65
183	Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108.	0.8	64
184	Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 1999, 16, 38-43.	1.4	63
185	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
186	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295.	0.6	62
187	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211.	1.0	60
188	Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926.	2.2	60
189	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	6.7	60
190	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	2.7	59
191	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	10.7	59
192	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842.	0.6	57
193	Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, .	3.9	56
194	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.8	55
195	Primary pulmonary hypertension: Current therapy. Progress in Cardiovascular Diseases, 2002, 45, 115-128.	3.1	54
196	Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196.	5.6	54
197	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944.	1.9	53
198	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83.	6.7	53

#	Article	IF	Citations
199	Quality of life in patients with chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2016, 48, 526-537.	6.7	52
200	Surgical Management of Unresolved Pulmonary Embolism. Chest, 1995, 107, 52S-55S.	0.8	51
201	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	4.1	51
202	Human Immunodeficiency VirusnefSignature Sequences Are Associated with Pulmonary Hypertension. AIDS Research and Human Retroviruses, 2012, 28, 607-618.	1.1	50
203	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.8	50
204	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.6	50
205	Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229.	6.7	50
206	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 925-928.	5.6	49
207	Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. Proceedings of the American Thoracic Society, 2006, 3, 601-607.	3.5	48
208	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	7.1	48
209	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. European Respiratory Review, 2013, 22, 487-494.	7.1	47
210	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. International Journal of Cardiology, 2014, 172, 332-339.	1.7	47
211	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112.	2.5	47
212	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303.	0.8	46
213	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	1.0	46
214	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
215	Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444.	6.7	44
216	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072.	6.7	43

#	Article	IF	Citations
217	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881.	0.8	43
218	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
219	Sexâ€specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. Journal of Thrombosis and Haemostasis, 2020, 18, 151-161.	3.8	42
220	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016.	1.8	42
221	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605.	0.9	41
222	A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759.	5.6	40
223	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	7.1	40
224	Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340.	6.7	40
225	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
226	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.	0.6	39
227	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65.	3.6	38
228	Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 411-420.	2.1	37
229	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242.	0.6	37
230	Pre-implantation genetic diagnosis in pulmonary arterial hypertension due toBMPR2mutation: Figure 1â€“. European Respiratory Journal, 2012, 39, 1534-1535.	6.7	35
231	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294.	3.2	35
232	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000673.	6.7	35
233	Estimating Right Ventricular Stroke Work and the Pulsatile Work Fraction in Pulmonary Hypertension. Chest, 2013, 143, 1343-1350.	0.8	34
234	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart, 2017, 103, 599-606.	2.9	34

#	Article	IF	Citations
235	Diagnostic value of D-dimer in patients with suspected pulmonary embolism: Results from a multicentre outcome study. Thrombosis Research, 2007, 120, 195-200.	1.7	33
236	Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265.	2.6	33
237	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394.	0.8	33
238	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	2.5	33
239	Cardiopulmonary Effects of a Single Oral Dose of Almitrine at Rest and on Exercise in Patients with Hypoxic Chronic Airflow Obstruction. Chest, 1986, 89, 174-179.	0.8	32
240	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, 2002, 63, 227-246.	1.2	32
241	Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2017, 49, 1602522.	6.7	32
242	Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine, 2010, 16, S11-S19.	2.6	31
243	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	1.3	29
244	Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198.	2.5	29
245	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567.	1.7	28
246	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	2.2	27
247	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520.	0.8	26
248	Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416.	1.9	26
249	Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100.	1.9	25
250	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35.	1.7	25
251	Treatments for severe pulmonary hypertension. Lancet, The, 1999, 353, 338-340.	13.7	24
252	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24

#	Article	IF	Citations
253	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. Journal of Heart and Lung Transplantation, 2021, 40, 1009-1018.	0.6	24
254	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
255	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596.	1.8	23
256	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 689-697.	0.6	23
257	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Medicine, 2017, 17, 216.	2.0	23
258	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
259	Sildenafil for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 6-7.	5.6	22
260	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205.	3.3	22
261	Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2018, 154, 521-531.	0.8	22
262	Pulmonary arterial hypertension and its association with HIV infection: an overview. Aids, 2008, 22, S1-S6.	2.2	21
263	Riociguat for Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 2266-2268.	27.0	21
264	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	6.7	21
265	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.	0.8	21
266	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477.	2.6	20
267	New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131.	1.8	20
268	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110.	0.6	20
269	Pulmonary Arterial Hypertension and HIV Infection. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 440-447.	2.1	19
270	Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202.	0.6	19

#	Article	IF	Citations
271	Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest, 2005, 128, 552S-553S.	0.8	17
272	Future perspectives in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 381-389.	7.1	17
273	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250.	2.6	17
274	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
275	Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nature Clinical Practice Rheumatology, 2005, 1, 93-101.	3.2	16
276	A prospective study of the 6â€…min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ¯ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465.	0.9	16
277	The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238.	7.1	15
278	Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. Respiration, 2013, 85, 464-470.	2.6	15
279	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22.	2.9	15
280	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398.	0.6	15
281	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.6	15
282	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	6.7	15
283	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opinion on Pharmacotherapy, 2005, 6, 1337-1348.	1.8	14
284	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550.	6.7	13
285	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 348-355.	0.6	13
286	Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954.	0.8	13
287	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
288	Vasodilators in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 202-203.	5.6	12

#	Article	IF	Citations
289	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	7.1	12
290	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541.	5.6	12
291	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	5.6	12
292	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	6.7	12
293	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, S74-S80.	2.9	11
294	Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2021, 177, 106293.	2.9	11
295	The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073.	2.5	11
296	Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Current Opinion in Pulmonary Medicine, 2010, 16, S43-S46.	2.6	10
297	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
298	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656.	0.6	10
299	Snoring and Obstructive Sleep Apnea: Objective Efficacy and Impact of a Chairside Fabricated Mandibular Advancement Device. Journal of Prosthodontics, 2017, 26, 381-386.	3.7	10
300	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.8	10
301	Pulse wave reflection in pulmonary hypertension. Journal of the American College of Cardiology, 2002, 39, 743.	2.8	9
302	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.6	9
303	Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. Chest, 2011, 140, 1066-1068.	0.8	8
304	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
305	Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315.	3.2	8
306	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92.	2.6	7

#	Article	IF	Citations
307	Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300.	6.7	7
308	The French registry of pulmonary arterial hypertension in children: rationale and design. Current Medical Research and Opinion, 2007, 23, S27-S33.	1.9	6
309	Future Directions in Chronic Thromboembolic Pulmonary Hypertension. Disease at a Crossroads?. Annals of the American Thoracic Society, 2016, 13, S255-S258.	3.2	6
310	Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 704-706.	5.6	6
311	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	1.7	6
312	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150.	1.7	6
313	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214.	6.7	5
314	New Formula for Predicting Mean Pulmonary Artery Pressure. Chest, 2005, 128, 467.	0.8	4
315	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. Current Opinion in Pulmonary Medicine, 2010, 16, S21-S26.	2.6	4
316	Safety of Therapeutic Doses of Tinzaparin During Pregnancy. Gynecologic and Obstetric Investigation, 2015, 79, 256-262.	1.6	4
317	Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8.	1.7	4
318	A paradigm shift in pulmonary arterial hypertension management. European Respiratory Review, 2013, 22, 423-426.	7.1	3
319	New horizons in pulmonary arterial hypertension management. European Respiratory Review, 2014, 23, 408-409.	7.1	3
320	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. European Respiratory Review, 2014, 23, 260-263.	7.1	3
321	Reply. Journal of the American College of Cardiology, 2014, 63, 2882-2883.	2.8	3
322	Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€• Circulation, 2015, 132, e154.	1.6	3
323	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. Journal of Clinical Monitoring and Computing, 2017, 31, 903-910.	1.6	3
324	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	4.7	3

#	Article	IF	Citations
325	Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2006, 7, 1133-1138.	1.8	2
326	GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.6	2
327	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	2.9	2
328	The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228a-229.	5.6	1
329	Bosentan in mild pulmonary hypertension â€“ Authors' reply. Lancet, The, 2008, 372, 1731-1732.	13.7	0
330	Editors' perspective and conclusions. Aids, 2008, 22, S63-S67.	2.2	0
331	Classification de lâ€™hypertension pulmonaire. Archives of Cardiovascular Diseases Supplements, 2010, 2, 132-136.	0.0	0
332	Updated Clinical Classification of Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 1-13.	0.1	0
333	Pulmonary Hypertension in Sickle Cell Disease. Progress in Respiratory Research, 2012, , 137-142.	0.1	0
334	Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1364-1365.	5.6	0
335	Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250.		0
336	Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244.		0